Biotech Industry Cooks up PR Plans to Get us to Swallow Synthetic Biology Food
By Dana Perls,
Food and Technology Blog
| 05. 22. 2014
Two Mondays ago, I sat in a room of some of the most powerful agribusiness, food and synthetic biology companies in the world. The goal of this industry meeting was to discuss how to get the public to accept synthetic biology, a new and unregulated set of genetic engineering methods, as the “foundation for the future of sustainable food.” It was meant to be a closed door and off-the-record industry meeting, in contrast to the open public forum on synthetic biology in our food which I helped organize the week before. But after some of the companies caught wind that Friends of the Earth was going to expose the leaked meeting information, we were cordially urged to attend by the meeting organizers.
Although there is no agreed upon definition of synthetic biology, it is a term that encompasses a variety of new, and many would say, “extreme” genetic engineering approaches, including computer generated DNA, directed evolution, and site specific mutagenesis. It’s faster and uses more powerful methods to engineer new genetic sequences than “traditional” genetic engineering. Engineers can even...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...